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Objective. To determine the cost-effectiveness of three alternative high-quality treat-
ments for attention deficit hyperactivity disorder (ADHD) relative to community care
(CC) and to determine whether cost-effectiveness varies with the presence of comorbid
disorders.
Data Sources/Collection. The study included 579 children ages 7–9.9 with diag-
nosed ADHD at six sites. Data for the study were distilled from administrative data and
from interviews with parents, including estimates of the child’s functional impairment.
These analyses focus on changes in functional impairment over 14 months.
Study Design. The study involved a large clinical trial that randomized participants to
one of four arms: routine CC, intensive medication management (MedMgt), multi-
component behavioral treatment, and a combination of behavioral treatment and
medication.
Principal Findings. We assessed the cost-effectiveness of the alternatives using costs
measured from a payer perspective. The preferred cost-effective treatment varies as a
function of the child’s comorbidity and of the policy maker’s willingness to pay. For pure
(no comorbidity) ADHD, high-quality MedMgt appears likely to be cost-effective at all
levels of willingness to pay. In contrast, for some comorbid conditions, willingness to
pay is critical: the policy maker with low willingness to pay likely will judge MedMgt
most cost-effective. On the other hand, a policy maker willing to pay more now in
expectation of future costs savings (involving, for example, juvenile justice), will rec-
ognize that the most cost-effective choice for comorbid conditions likely involves be-
havior therapy, with or without medication.
Conclusions: Analyses of costs and effectiveness of treatment for ADHD must con-
sider the role of comorbidities.
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Attention problems are among the most common of mental/emotional/be-
havioral disorders among children and youth (U.S. Department of Health and
Human Services 1999). Youth with attention deficit hyperactivity disorder
(ADHD) are more likely to be involved in a variety of costly behaviors in-
cluding substance use and abuse (Daley 2004) and delinquency (Richardson
2002) as well as to receive costly services. These children also are likely to
receive additional school services, including (but not limited to) special ed-
ucation ( Jones, Foster, and Gottschall 2005). Jones et al. (2005) estimate that
the costs of such services can exceed $10,000 per year. These costs represent
only some of the costs that appear on public budgets. These behaviors gen-
erate even larger costs to society, such as the costs to victims of violence or the
broader costs of school failure (Haveman and Wolfe 1984). These figures
suggest that a policy maker’s willingness to pay for effective treatments should
be quite high. As discussed below, this willingness to pay is a key determinant
of a program’s cost-effectiveness.
Fortunately, effective treatments exist, notably behavioral treatment and
psycho-stimulants. A key issue in the field involves the degree to which each of
these treatments is more (or less) effective and cost-effective when combined
with the other ( Jensen 2000).
Assessment of treatment effectiveness is complicated by comorbidities,
including conduct disorder and anxiety. These conditions amplify the link
between ADHD and service use (Vostanis et al. 2003) and raise the risk for
poor long-term outcomes, such as violence and substance abuse (Arseneault
et al. 2000).
In contrast to efficacy and effectiveness, little is known about the cost-
effectiveness of alternative treatments, either separately or in combination. To
address this issue, we use data from one of the largest and most influential
studies in the field, the Multimodal Treatment Study of Children with ADHD
(MTA) (The MTA Cooperative Group 1999). The MTA was designed
to compare the effectiveness of psychosocial (behavioral) treatment versus
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medication, and determine whether the two modalities are more effective
when delivered together.
An earlier cost-effectiveness analysis of MTA data focused on core at-
tention and related symptoms in the whole sample ( Jensen et al. 2005). The
analyses presented here extend that earlier work in three ways. First, we
examine a broader measure of functional impairment, the Columbia Impair-
ment Scale (CIS). Second, we examine how cost-effectiveness varies with
comorbidities. Third, we use new methodology for examining cost-effective-
ness of treatments, the cost-effectiveness acceptability curve (CEAC) (Hoch,
Briggs, and Willan 2002).
PRIOR RESEARCH
Two areas of prior work inform this research: that on the cost-effectiveness of
treatment for ADHD and earlier research on MTA.
Prior Research on Cost-Effectiveness of Treatment for ADHD
In addition to the Jensen et al. analyses (discussed below), economic evalu-
ations of ADHD treatment have been published for Canada and the United
Kingdom (UK). Miller et al. (1998) compared six treatments: methylpheni-
date, dextroamphetamine, pemoline (high-dose and low-dose), nondrug ther-
apy, combined therapy, and no treatment. The study considers costs and
outcomes over a 1-year period; the study’s perspective is that of third-party
payers. On the basis of prior research, treatment effects were determined using
a measure of symptoms, the Conners Teacher Rating Scale (CTRS). The
methylphenidate strategy was more effective and cheaper than other med-
ication therapies and behavioral therapy as well as combination therapy.
Relative to no treatment, methylphenidate was associated with incremental
costs of 498 CAN-$ per 6-point (or 1 SD) improvement of the CTRS score.
In the United Kingdom, Gilmore and Milne (2001) examined the cost-
effectiveness of different medications from the perspective of the UK National
Health Service (NHS). Methylphenidate was cost-effective in children with
hyperkinetic disorder according to ICD-10 criteria. This study considered
neither behavioral nor combined treatment strategies, however (Gilmore and
Milne 2001). The UK National Institute of Clinical Excellence (NICE) esti-
mated the cost per quality-adjusted life year (QALY) gained by methylpheni-
date at d9,200 to d14,600 (Lord and Paisley 2000). In a further study from the
perspective of the UK NHS, a once-daily modified-release preparation of
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methylphenidate showed extended dominance over immediate-release me-
thylphenidate (both combined with behavioral treatment) over a wide range
of assumptions (Schlander 2004). To date, all UK analyses have used a 1-year
time horizon.
Prior Research on MTA
The MTA study has been the subject of substantial research and some debate.
Five hundred and seventy-nine children ages 7–9.9 were randomized to one of
four treatment arms: assessment and referral to community care (CC); inten-
sive, systematic medication management (MedMgt); multicomponent beha-
vioral treatment (Beh); and a combination of behavioral treatment and
medications (Comb). The MTA-administered interventions were high quality.
In the case of MedMgt, dosage was carefully titrated, and participants met with
their physician monthly, who consulted the child’s teacher regarding class-
room performance. Beh was multicomponent and targeted multiple aspects of
the child’s life. (For details, see Wells et al. 2000.) These components included
parent training, a two-part school intervention component, and a child treat-
ment component anchored in an intensive summer treatment program. Each
treatment continued for 14 months, although Beh was faded to monthly parent
group sessions over the last 3–5 months.
Results indicated that for ADHD symptoms, children receiving Comb
or MedMgt showed significantly greater improvement than those given CC or
Beh alone. Much debate focused on the question of whether the study really
implied that medication (only) was the ideal treatment. Although preliminary
reports in the media seemed to support this claim, the full portfolio of findings
was more nuanced. The most dramatic findings focused on symptoms, but
analyses of broader outcomes (such as social skills, parent–child relationship,
and academic performance) revealed that the combination therapy was mod-
estly superior to medication alone (Swanson et al. 2001).
METHODS
Data
The MTA study collected a comprehensive battery of assessments, and our
analyses focused on three key measures: the CIS (a comprehensive measure of
child functioning) (Bird, Shaffer, Fisher, Gould, Stagnezza et al. 1993); the
Services for Children and Adolescents, Parent Interview (SCAPI, a measure of
service use Hoagwood et al. 2004; P. Jensen, Hoagwood et al. 2004) and the
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Diagnostic Interview Schedule for Children (Shaffer et al. 1993), used to assess
the presence of DSM-IV diagnoses, including ADHD, conduct disorder, de-
pression, and anxiety disorders.
The CIS is a 13-item questionnaire completed by parents and measures
impairments in the preceding 6 months across four areas: interpersonal re-
lations, broad psychopathology domains (for example, depression, anxiety, or
behavior problems), schoolwork, and use of leisure time (Bird et al. 1993).
The scale has good internal consistency and construct validity and has been
used in multiethnic samples. The analyses below focus on the change in im-
pairment between baseline and the 14-month treatment endpoint.
Use of mental health services was assessed using the revised SCAPI. This
measure was administered at 3-month intervals during treatment and asked
the families to report on the use of any medical and school services, com-
munity mental health services, or juvenile justice services. This measure pro-
vided information on the specific types and amounts of services used,
medication costs, and costs associated with primary care versus specialty
mental health services. Reliability and validity of this measure are excellent
(Hoagwood et al. 2004; Jensen et al. 2004).
Comorbidity Subgroups
Following procedures outlined in Jensen, Hinshaw et al. (2001), we defined
four comorbidity subgroups: ADHD-only (32 percent), ADHD1internalizing
comorbidities only (anxiety or depression) (14 percent), ADHD1externaliz-
ing comorbidities only (conduct or oppositional defiant disorder) (30 percent),
and ADHD1both comorbidities (25 percent).
Costs of Treatment
As in the Miller et al. (1998) study, all costs were included regardless of
whether they were paid for by a patient, an insurer, or any other third party.
Although not accounting for the discounts offered and negotiated fees ob-
tained by various parties, this approach approximates a payer perspective
( Jensen et al. 2005). The direct costs associated with providing each of the
treatment arms were calculated by using the real treatment costs of the MTA
Study, while excluding costs associated with the research component of the
study, such as research staff time and costs associated with administering the
study instruments. All the costs were assumed equal across sites and
were adjusted for inflation to year 2000 dollars by using the consumer price
index.
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Costs of the medications were calculated by using the National Data
Drug File Plus (http://www.firstdatabank.com/knowledge_bases/nddf_plus/).
It provides average wholesale prices of all drugs from various pharmaceutical
companies and in varying pill sizes. The following prices were used for each
medication: Ritalin, Novartis, 10-mg pill, 0.059b/mg; Dexedrine, Smith-
Kline Beecham, 10-mg pill, 0.092b/mg; imipramine, Allscripts, 50-mg pill,
0.013b/mg; Cylert, Abbott Pharmaceutical, 37.5-mg pill, 0.046b/mg; and
bupropion, Geneva, 100-mg pill, 0.009b/mg.
The costs of the psychiatrist, psychologist, pediatrician, teacher,
and aide times were calculated using the hourly wage for these professionals
based on their respective annual salaries. The adjusted yearly salary
of the psychiatrists with the consumer price index was determined to be
$142,919.80, based on data from the American Medical Association’s
Socioeconomic Monitoring System survey (Center for Health Policy
Research 1999). Psychologist salaries were calculated as $80,523.24
(Scheffler, Ivey, and Garrett 1998). Teacher salaries (for those who
worked in the summer treatment program) and teachers’ aides’ salaries
were determined using data from the Bureau of Labor Statistics. Appropriate
levels of fringe benefits were added to the salaries to capture total compen-
sation. (For teacher’s aides, a rate of 23.5 percent was used; for psychologists
and psychiatrists, we used a rate of 27.4 percent.) Finally, the cost of the
summer treatment program was calculated using hourly wages of program
staff.
Statistical Methods: CEAC
Traditional methods of cost-effectiveness analysis revolve around incremental
cost-effectiveness ratios (ICERs) (Drummond et al. 1997). Until recently,
ICERs were often provided with no sense of the precision of the estimates.
Addressing this problem, however, turned out to be easier said than done,
largely because of the irregular statistical properties of ratios. A variety of
solutions have been proposed involving the delta method, Feiler’s method,
and bootstrapping (Briggs, Wonderling, and Mooney 1997).
Even if a satisfactory confidence interval of sorts could be developed,
conceptual problems remain. In particular, negative regions of the confidence
interval are difficult to interpret. A negative ICER may mean that a new
treatment is more costly and less effective than the old or that it is less costly
and more effective. Clearly, the implications for the decision maker are dif-
ferent (indeed, completely opposite).
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For that reason, two alternatives have been proposed: net benefits (NB)
and the closely related net health benefits. Although both involve manipu-
lating the cost-effectiveness ratio, we use the former here (Lothgren and
Zethraues 2000; Sendi and Briggs 2001; Hoch et al. 2002).
The key question in cost-effectiveness is whether the ICER of a new
treatment relative to an existing one exceeds a policy maker’s or society’s
willingness to pay (lc) for the outcome of interest. This outcome is measured in




< lc : ð1Þ
Because of sampling error, this statement is probabilistic, and thus confidence
intervals for the ICER are needed. As mentioned above, the bounds of this
interval can be difficult to calculate and/or interpret. For that reason, one can
manipulate (1) into the following:
lc  ð ENewTx  EUsualTxÞ  ð CNewTx  CUsualTxÞ > 0 ð2Þ
(2) represents ‘‘NB,’’ and a positive value of NB clearly indicates that the new
treatment is preferred. A key feature of equation (2) is that it no longer involves
a ratio and that one can calculate the P (NB40) at alternative values of l, and
these values can be plotted, generating the so-called CEAC. The CEAC pro-
vides the policy maker with the information he or she needs——what is the
probability the new treatment is cost-effective at alternative values of the out-
come of interest (or levels of willingness to pay) (Claxton 1999). All analyses
were conducted with STATA version 8 (StataCorp. 2004).
RESULTS
Tables 1 and 2 describe the sample’s demographics as well as key variables
across the four treatment arms. The latter provides the mean for costs and
functional impairment as well as the 95 percent confidence intervals. Three
features of Table 2 stand out. First, one can see that the average individual
improved, regardless of comorbidity conditions or treatment arm. (Improve-
ment corresponds to negative values of the CIS variable.) The CIS scores have
been standardized so comparisons across groups or treatments correspond to
effect sizes. Second, for a given comorbidity condition, costs vary across the
four treatment arms in every instance and outcomes vary across arms for two
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of the four comorbidity conditions. The two exceptions involve functioning
for the ADHD (only) subgroup and for the conduct-disordered subgroup
( p 5 .40 and .16, respectively). Third, within a treatment arm, outcomes and
costs varied a good deal less across comorbidity conditions. Supplemental
analyses reveal that the variation in costs was not significant for any of the four
arms. To some extent, functional impairment did vary. For three arms, var-
iation across subgroups is significant at the .05 level.
How large are these effects in terms of changes in behaviors that parents,
providers, and policy makers value? To assess their practical magnitude, one
can look at specific items in the scale. For example, for the comorbid conduct
disordered, moving from CC to combination therapy reduces the likelihood
that ‘‘getting into trouble’’ is a ‘‘bad problem’’ from 19 to 7 percent. For
those with comorbid anxiety, moving from CC to the other arms reduces
the likelihood that ‘‘behavior at school’’ is a ‘‘bad problem’’ from 50 to 10
percent.
Figure 1 provides the CEAC for the entire sample. The outcome in this
case is a continuous variable——the WTP figures (l) correspond to a 1 SD
improvement in functioning. For each value of l (on the horizontal axis), the








Behavioral ADHD only 43 81 72 19 5 5
Anxiety (Anx) 23 83 39 48 13 0
Conduct disorder (CD) 42 76 55 19 10 17
CD–Anx 36 78 56 25 8 11
Combination ADHD only 53 83 64 9 8 19
Anx 19 74 74 11 16 0
CD 36 78 47 28 3 22
CD–Anx 37 76 59 22 16 3
Community ADHD only 42 71 64 17 7 12
Anx 19 84 58 21 5 16
CD 54 85 61 19 4 17
CD–Anx 31 87 61 16 13 10
Medication
management
ADHD only 46 83 63 20 11 7
Anx 20 75 55 20 10 15
CD 40 83 73 20 3 5
CD–Anx 38 84 58 18 11 13
Total 579 80 61 20 8 11
ADHD, attention deficit hyperactivity disorder.
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net health benefits were calculated for each individual. This tabulation in-
volved a simple function of the improvement they experienced multiplied by
l, and from this figure, costs were subtracted. Then using bootstrapping (with
500 replications) the probability that a given treatment had the highest NB was
calculated for each arm. This probability is plotted on the vertical axis. At
modest levels of willingness to pay, MedMgt is nearly certain to be cost-
effective. At somewhat higher levels of willingness to pay, Comb therapy
becomes cost-effective. Beh therapy is dominated——other treatments are more
effective and less costly (Drummond and Mcguire 2001).
Table 2: Costs and Change in Functioning, by Treatment Arm and Comor-
bidity Status
Comorbidity Treatment Arm Obs
Functioning Costs
Mean (95% CI) Mean (95% CI)
ADHD only Med_Man 36  0.92  1.26  0.59 $ 979 $ 807 $ 1,151
ADHD only Behavioral 35  0.70  1.00  0.40 $ 6,133 $ 5,749 $ 6,516
ADHD only Combination 38  0.86  1.14  0.58 $ 7,064 $ 6,815 $ 7,314
ADHD only Community 32  0.60  0.87  0.34 $ 975 $ 543 $ 1,408




Anxiety Med_Man 15  0.77  1.26  0.27 $ 1,209 $ 977 $ 1,441
Anxiety Behavioral 18  1.18  1.75  0.62 $ 5,552 $ 4,699 $ 6,405
Anxiety Combination 15  0.71  1.25  0.16 $ 7,147 $ 6,800 $ 7,494
Anxiety Community 16  0.21  0.71 0.29 $ 618 $ 406 $ 831




CD Med_Man 31  1.14  1.56  0.73 $ 1,099 $ 876 $ 1,323
CD Behavioral 31  0.88  1.26  0.49 $ 6,303 $ 6,054 $ 6,553
CD Combination 28  1.43  1.85  1.01 $ 7,131 $ 6,857 $ 7,404
CD Community 40  0.93  1.23  0.62 $ 1,034 $ 658 $ 1,410
Significance level
(across arms)
130  1.07  1.26  0.89 $ 3,619 $ 3,107 $ 4,132
0.16 0.00
CD–Anx Med_Man 22  1.37  1.88  0.86 $ 1,119 $ 856 $ 1,382
CD–Anx Behavioral 27  1.50  1.97  1.03 $ 6,342 $ 6,066 $ 6,619
CD–Anx Combination 34  1.59  1.92  1.26 $ 6,800 $ 6,371 $ 7,230
CD–Anx Community 24  0.78  1.17  0.39 $ 942 $ 488 $ 1,397
Significance level
(across arms)
107  1.34  1.55  1.13 $ 4,203 $ 3,640 $ 4,766
0.03 0.00
ADHD, attention deficit hyperactivity disorder; CI, confidence interval; CD, conduct disorder;
Anx, anxiety.
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Figure 2, however, provides CEAC for the four subgroups. Although
MedMgt appears cost-effective at all levels of willingness to pay for ADHD-
only children, the picture changes for ADHD-Anx children: Beh may be cost-
effective choice at higher levels of willingness to pay. Likewise, for youth with
ADHD and comorbid CD/ODD-only, MedMgt may be cost-effective choice
at low levels of willingness to pay, but Comb may be the more likely cost-
effective choice at higher levels of willingness to pay. And for ADHD1CD/
Anx youth, MedMgt is the only treatment with a reasonable probability of
being cost-effective but that occurs only at very low levels of willingness to pay.
Figure 3 shows the precision of the statistical uncertainty surrounding the
choice of treatment for children and youth in the different subgroups. In some
instances, the resulting estimate is rather imprecise, reflecting substantial un-
certainty. However, note that the estimates of net health benefits are still large
in practical terms. To highlight this fact, we present box and whisker plots for
net health benefits for each treatment and combordity subgroups at one level
of willingness to pay, $50,000. Nearly all of the distributions are positive
(i.e., to the right of the broken line at 0). For those with both comorbidities,
for example, one can see that the three high-quality treatments all
average roughly $75,000 in net health benefits. Those estimates are very
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Figure 1: Likelihood of Cost-Effectiveness for Improved Functioning;
by Treatment Arm
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Particularly revealing is the fact that the potential net health benefits are
greatest for the group for which the statistical uncertainty is also greatest.
DISCUSSION
These analyses generate several important insights into the choices that a
policy maker may face when deciding how to use scarce health care dollars to
improve health outcomes for children with ADHD. First, our analyses reveal
that the cost-effective treatment varies as a function of the child’s comorbidity
and of the policy makers’ willingness to pay. For ‘‘pure’’ (no comorbidity)
ADHD high-quality medication care (MedMgt) appears certain to be cost-
effective at all levels of willingness to pay. In contrast, for comorbid conditions,
willingness to pay is critical: the policy maker who is willing to pay only a little
likely will judge MedMgt cost-effective. On the other hand, a policy maker
willing to pay more now to avert future costs (involving, for example, juvenile
justice) may recognize that the most cost-effective choice likely involves be-
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These analyses also indicate that in instances of comorbid ADHD (with
both anxiety-depression and conduct/oppositional disorders), considerable
uncertainty faces the policy maker seeking to make a cost-effective choice. For
these complex cases, the likelihood of making a cost-effective choice falls
dramatically: a policy maker hoping to pay (or avert) $30,000 or more has at
best a 50–50 chance of making a cost-effective choice when opting for Comb
interventions. Alternatively, for the policy maker willing to pay (hoping to
eventually avert) $10,000 for high-quality MedMgt, the likelihood of making a
cost-effective choice is high (above 80 percent), but this falls dramatically if the
policy maker is hoping for cost-savings greater than that.
Similar to the findings of the original report by Jensen et al., these findings
suggest that under many (but not all) circumstances, high quality MedMgt offers
the policy maker reasonable certainty of making a cost-effective choice, but in
instances of specific comorbidities and at higher levels of willingness to pay,
intensive behavior therapy (for ADHD/Anx children) and combined treat-
ments (for ADHD with CD/ODD) may be cost-effective choices. Our findings
demonstrate that high costs alone do not rule out cost-effectiveness; however,
such treatments may be more likely to be cost-effective when carefully targeted.
Future studies must address whether these findings apply to longer-term follow-
up periods, other types of outcomes, or other patient subgroups or risk profiles.





































Figure 3: Magnitude and Precision of Net Health Benefits
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POLICY IMPLICATIONS
These results suggest that the ‘‘either medication or therapy’’ choice that often
roils mental health policy is a false one. Optimal treatment may involve both
types of treatment, and this conclusion is emerging for several disorders (e.g.,
the treatment of depression in adolescents [March et al. 2004]). The MTA
Study grew a great deal of attention from researchers and policy makers
regarding the superiority of MedMgt to behavior therapy alone (Pelham
1999). As earlier research showed, however, the apparent advantage of Med-
Mgt was greatest for symptoms. Regarding functioning, this research shows
that behavior therapy plays a key role for two of the three groups for which
definitive recommendations can be made.
Obtaining high-quality combination treatment in the real world, how-
ever, may be easier said than done. Medicaid and SCHIP are major sources of
funding for children’s mental health services, and the coverage they provide
could in theory finance combination therapy like that offered under MTA
(Howell 2004). As evinced by the experiences of those in the CC arm, how-
ever, the care actually received may fall far short of those standards (Semansky
and Koyanagi 2003). Other studies of larger community samples confirm
that only a minority of children receive multimodal therapy (dosReis et al.
2004).
A variety of barriers hinder receipt of high-quality services, including
stigma and low reimbursement rates, as they do the receipt of any mental
health services (U.S. Surgeon General 1999). Additional barriers, however,
are specific to children’s mental health, including limitations in the number of
relevant professionals. (For example, there are only 5,000 child psychiatrists
practicing in the entire United States [Manderscheid and Henderson 2001].)
These problems may worsen as states struggle with the high costs of
Medicaid coverage, especially prescription drugs. (One common limitation,
limiting coverage to generics, is likely to affect care less for attention deficit
disorder than for other disorders for which front-line medications are not
available in generic form [Koyanagi, Forquer, and Alfano 2005].)
Another key policy implication involves the redistribution of resources
among children and youth with attention problems. One implication of these
analyses is that MedMgt alone may be cost-effective for cases uncomplicated
by other comorbidities. Providing these cases with high-quality MedMgt may
free resources needed to provide more costly treatment to more complex
cases. It is striking that for no subgroup was behavioral treatment alone
cost-effective. If upheld by longer-term results, these findings suggest that
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individuals should be provided with either more or less intensive (and costly)
treatment, depending on the nature of their comorbid conditions but that such
treatments should as a rule include high-quality MedMgt.
Finally, a key to interpreting these policy implications involves the
practical sense in which these treatments are cost-effective. Although we have
measured the costs of the treatments from a payer perspective, we have con-
sidered the benefits of the treatment from a broader perspective, that of a
policy maker. Such a policy maker, however, would have to realize that many
of the benefits of these model treatments are experienced outside of the mental
health sector. Many of the benefits, for example, would accrue to the criminal
or juvenile justice systems or even outside of government altogether (e.g., the
costs to victims). Such savings are indeed the justification for many public
programs. However, it often takes a far-sighted policy maker to recognize that
expenditures on better mental health services now may be realized outside of
that agency and only over time. As policy makers consider implementing
evidence-based treatments in real-world settings, this issue will recur——better
treatments may not be less costly for the mental health agency but may pro-
duce substantial benefits for society over time.
LIMITATIONS OF THE STUDY
The study has several limitations. First, the CC arm may not generalize be-
yond the communities included as study sites, which typically were in and
around academic medical centers. Given that context, it is striking that ‘‘treat-
ment as usual’’ fared so poorly given the resources likely available in those
communities. Second, the measure of treatment costs is limited to the use of
mental health services. However, services use in other sectors (such as child
welfare) might potentially influence a policy maker’s willingness to pay and
could be included in a benefit–cost analysis. This area is an important one for
future research.
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